| 1 |
34190693 | Effect of Bortezomib Regimens and Daratumumab Monotherapy on Cellular Immunity in Multiple Myeloma Patients. | 2021 Jun |
1 |
| 2 |
31043801 | Selective purging of human multiple myeloma cells from peripheral blood mononuclear cells: a preliminary study. | 2019 |
1 |
| 3 |
29196043 | Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. | 2018 Jan 28 |
4 |
| 4 |
30079070 | CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. | 2018 |
1 |
| 5 |
28232617 | Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. | 2017 Jul |
1 |
| 6 |
27611189 | Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity. | 2016 |
2 |
| 7 |
25398450 | Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. | 2015 Jun 15 |
1 |
| 8 |
22024108 | Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. | 2012 Feb |
1 |
| 9 |
20956803 | Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. | 2011 Jan 13 |
2 |